Bevacizumab in combination with chemotherapy improves progression-free survival (PFS) in metastatic breast cancer and has a good safety profile. a study conducted by Makhoul et al. showed that bevacizumab in combination with chemotherapy improved the pathological complete remission rate (pCR) in patients with poor prognosis breast cancer and that toxicities were easily managed. The study enrolled 40 patients, with a mean age of 46 years, with breast cancer stage T1 to 4 and/or positive axillary lymph nodes. A TCB regimen (doxorubicin, cyclophosphamide, bevacizumab) was given for 3 weeks × 4, followed by adriamycin (A) for 3 weeks × 4. Breast-conserving surgery was considered for those with good outcome, and radical surgery with pCR evaluation was performed for those with poor outcome. Bevacizumab was given from 28 to 84 days after surgery (after complete healing of the surgical incision), and radiotherapy, trastuzumab therapy, and endocrine therapy were added according to indications. The results showed that 32 cases completed all treatment cycles. 21 cases had cCR and 16 cases had cPR, 1 case progressed, and 1 case had no change. 38 cases were treated surgically, of which 10 cases were treated with simple lumpectomy and 28 cases were treated radically. 16 of 39 cases had breast pCR and 13 cases had breast and axillary lymph node pCR (41% breast pCR and 33% breast and axillary pCR). Neoadjuvant chemotherapy is currently a hot research topic in the clinical field of breast cancer, of which neoadjuvant regimen design should be the key. The results of this study show that bevacizumab in combination with chemotherapy is a highly effective neoadjuvant regimen, achieving a 41% pCR, significantly higher than the 26% achieved in the current classical B27 trial. The clinical value of this regimen may be even more prominent in the triple-negative patient population.